There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inovio Pharmaceuticals (NASDAQ: INO) and Ampliphi Biosciences (AMEX: APHB) with bullish sentiments.
Inovio Pharmaceuticals (NASDAQ: INO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ: INO), with a price target of $13. The company’s shares closed yesterday at $5.
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.8% and a 40.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Inovio Pharmaceuticals is Strong Buy and the average price target is $11.67, representing a 133.4% upside.
In a report issued on May 10, Maxim Group also maintained a Buy rating on the stock with a $8 price target.
See today’s analyst top recommended stocks >>
Ampliphi Biosciences (AMEX: APHB)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ampliphi Biosciences (AMEX: APHB), with a price target of $6. The company’s shares closed yesterday at $1.18.
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.8% and a 37.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Ampliphi Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $6.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
